CN112996541B - 去除衰老细胞的方法和衰老细胞的制备方法 - Google Patents

去除衰老细胞的方法和衰老细胞的制备方法 Download PDF

Info

Publication number
CN112996541B
CN112996541B CN201980073708.0A CN201980073708A CN112996541B CN 112996541 B CN112996541 B CN 112996541B CN 201980073708 A CN201980073708 A CN 201980073708A CN 112996541 B CN112996541 B CN 112996541B
Authority
CN
China
Prior art keywords
cells
senescent cells
senescent
bptes
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980073708.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN112996541A (zh
Inventor
中西真
城村由和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Original Assignee
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC filed Critical University of Tokyo NUC
Publication of CN112996541A publication Critical patent/CN112996541A/zh
Application granted granted Critical
Publication of CN112996541B publication Critical patent/CN112996541B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980073708.0A 2018-11-08 2019-11-07 去除衰老细胞的方法和衰老细胞的制备方法 Active CN112996541B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-210300 2018-11-08
JP2018210300 2018-11-08
PCT/JP2019/043570 WO2020095971A1 (ja) 2018-11-08 2019-11-07 老化細胞を除去する方法、および老化細胞の調製方法

Publications (2)

Publication Number Publication Date
CN112996541A CN112996541A (zh) 2021-06-18
CN112996541B true CN112996541B (zh) 2024-08-06

Family

ID=70612079

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980073708.0A Active CN112996541B (zh) 2018-11-08 2019-11-07 去除衰老细胞的方法和衰老细胞的制备方法

Country Status (5)

Country Link
US (2) US20220119768A1 (https=)
EP (1) EP3878470A4 (https=)
JP (1) JP7570100B2 (https=)
CN (1) CN112996541B (https=)
WO (1) WO2020095971A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7016983B1 (ja) * 2021-01-21 2022-02-07 株式会社ユーグレナ Ｇｌｓ１遺伝子阻害用化粧料組成物、ｇｌｓ１遺伝子阻害剤、老化細胞除去用化粧料組成物及び老化細胞除去剤
EP4346813A4 (en) * 2021-05-26 2025-08-06 Unity Biotechnology Inc METHODS OF TREATMENT OF RETINAL VASCULOPATHIES
US20250108036A1 (en) * 2021-11-10 2025-04-03 Lifeceutix Co., Ltd. Compositions for removing senescent cells and uses thereof
CN116008519A (zh) * 2022-12-14 2023-04-25 贵州医科大学 一种新型细胞衰老检测试剂盒及其检测方法和应用
CN120752045A (zh) * 2023-02-27 2025-10-03 协和医药化工股份有限公司 细胞衰老的预防或改善剂
CN121648114A (zh) * 2026-02-06 2026-03-13 北京大学 一种小分子化合物在制备用于抗衰老的产品中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106029659A (zh) * 2014-01-06 2016-10-12 理森制药股份公司 谷氨酰胺酶抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2141241A1 (en) * 2008-07-03 2010-01-06 Helmholtz-Zentrum für Infektionsforschung GmbH Senescence cells and methods for its production
US10221459B2 (en) * 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
WO2017008060A1 (en) * 2015-07-08 2017-01-12 Unity Biotechnology, Inc. Compositions and methods for treating senescence-associated diseases and disorders
US20170348398A1 (en) * 2016-06-03 2017-12-07 Vanderbilt University Compositions and methods for decreasing blood glucagon levels

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106029659A (zh) * 2014-01-06 2016-10-12 理森制药股份公司 谷氨酰胺酶抑制剂

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Downregulation of Polo-Like Kinase 1 Induces Cellular Senescence in Human Primary Cells Through a p53-Dependent Pathway;Hee-Jin Kim等;《Journals of Gerontology》;20130322;第68卷(第10期);1145–1156 *
Head and Neck Squamous Cell Carcinoma Metabolism Draws on Glutaminolysis, and Stemness Is Specifically Regulated by Glutaminolysis via Aldehyde Dehydrogenase;Pachiyappan Kamarajan等;《J Proteome Res》;20170303;第16卷(第3期);1315–1326 *
Hedgehog–YAP Signaling Pathway Regulates Glutaminolysis to Control Hepatic Stellate Cell Activation;Kuo Du等;《Gastroenterology》;20180430;第154卷(第5期);1465-1479 *
Hermann Unterluggauer等.Premature senescence of human endothelial cells induced by inhibition of glutaminase.《Biogerontology》.2008,(第9期),247-259. *
Hermann Unterluggauer等.Premature senescence of human endothelial cells induced by inhibition of glutaminase.《Biogerontology》.2008,(第9期),247–259. *
Necessary and Sufficient Role for a Mitosis Skip in Senescence Induction;Yoshikazu Johmura等;《Molecular Cell》;20170703(第55期);73-84 *
Premature senescence of human endothelial cells induced by inhibition of glutaminase;Hermann Unterluggauer等;《Biogerontology》;20080304(第9期);247–259 *
Tumor Necrosis Factor-InducesNeurotoxicity via Glutamate Release from Hemichannels of Activated Microglia in an Autocrine Manner;Hideyuki Takeuchi等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20060728;第281卷(第30期);21362–21368 *

Also Published As

Publication number Publication date
EP3878470A1 (en) 2021-09-15
JPWO2020095971A1 (ja) 2021-10-07
JP7570100B2 (ja) 2024-10-21
US20220119768A1 (en) 2022-04-21
US20260049282A1 (en) 2026-02-19
WO2020095971A1 (ja) 2020-05-14
EP3878470A4 (en) 2022-08-31
CN112996541A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
CN112996541B (zh) 去除衰老细胞的方法和衰老细胞的制备方法
US20250360129A1 (en) Compositions and methods of using tyrosine kinase inhibitors
Song et al. Inhibition of gasdermin D-dependent pyroptosis attenuates the progression of silica-induced pulmonary inflammation and fibrosis
US20150164901A1 (en) Compounds, compositions and methods for treating or preventing neurodegenerative disorders
CN111479570A (zh) 用于治疗与dux4表达相关的疾病的化合物
Cheng et al. LGALS3 regulates endothelial-to-mesenchymal transition via PI3K/AKT signaling pathway in silica-induced pulmonary fibrosis
JP6918839B2 (ja) 概日時計の乱れに関連するマイクロバイオームの調節異常を処置するための方法及び医薬組成物
WO2019180664A1 (en) Method for preventing or modulating fibrosis and fibrotic response associated with the integrated stress response
Li et al. Inhibitory effect of l-mimosine on bleomycin-induced pulmonary fibrosis in rats: Role of eIF3a and p27
JP2017096785A (ja) 組織線維化スクリーニング方法および抗組織線維化薬剤ならびに機能性食品
Hayes et al. Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin‐Deficient D2. B10‐Dmdmdx/J Mouse
CN114650818A (zh) 用于治疗与dux4表达相关的疾病诸如肌营养不良症和癌症的酪蛋白激酶1抑制剂
Li et al. Miconazole alleviates colitis by suppressing colonic senescence, NF-κB Signaling and gut microbiota modulation
WO2022052738A1 (zh) 环状RNA Cwc27下调剂在制备预防和/或治疗阿尔茨海默病的药物中的应用
EP4640238A1 (en) Therapeutic agent for pulmonary disease, hepatic disease or renal disease, which contains pgam-chk1 binding inhibitor
JP2019510061A (ja) 高脂肪食関連疾患を阻害する方法
CN115969975B (zh) Phgdh抑制剂在预防和/或治疗结直肠癌转移中的应用
CN110664815A (zh) 长春花碱iii在制备预防或治疗阿尔茨海默症药物中的应用
JP6873410B2 (ja) Ｐａｒ１阻害をメカニズムとする異所性骨化の治療薬剤
JP2023159469A (ja) 肥満症を予防又は治療するための医薬組成物
JP7525591B2 (ja) 心機能不全を予測及び処置するための方法
CN114560817B (zh) 一种用于抑制纤维化的小分子药物及其应用
Fuqua ULK1 and ULK2 modulate skeletal muscle homeostasis and whole-body metabolism
Zhu et al. Garlic‐Derived Exosomes Alleviate Intestinal Fibrosis in Crohn's Disease by Modulating PFKFB3‐Mediated Metabolic Reprogramming
Shu et al. The Limb-bud and Heart (LBH) promotes renal fibrosis through endoplasmic reticulum stress-induced pyroptosis and partial epithelial-mesenchymal transition in renal tubular epithelial cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant